List of Excipients in API tazemetostat
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing tazemetostat
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Epizyme Inc | TAZVERIK | tazemetostat | 72607-100 | FERRIC OXIDE RED | 2035-12-19 |
| Epizyme Inc | TAZVERIK | tazemetostat | 72607-100 | HYDROXYPROPYL CELLULOSE | 2035-12-19 |
| Epizyme Inc | TAZVERIK | tazemetostat | 72607-100 | HYPROMELLOSE | 2035-12-19 |
| Epizyme Inc | TAZVERIK | tazemetostat | 72607-100 | LACTOSE MONOHYDRATE | 2035-12-19 |
| Epizyme Inc | TAZVERIK | tazemetostat | 72607-100 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | 2035-12-19 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for tazemetostat
Excipient focus: FERRIC OXIDE RED
tazemetostat drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Epizyme Inc | tazemetostat | 72607-100 |
| >Company | >Ingredient | >NDC |
tazemetostat drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
tazemetostat drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Epizyme Inc | tazemetostat | 72607-100 |
| >Company | >Ingredient | >NDC |
tazemetostat drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
tazemetostat drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Epizyme Inc | tazemetostat | 72607-100 |
| >Company | >Ingredient | >NDC |
tazemetostat drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
tazemetostat drug variants containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Epizyme Inc | tazemetostat | 72607-100 |
| >Company | >Ingredient | >NDC |
tazemetostat drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
tazemetostat drug variants containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Epizyme Inc | tazemetostat | 72607-100 |
| >Company | >Ingredient | >NDC |
tazemetostat drug variants not containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
tazemetostat drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Epizyme Inc | tazemetostat | 72607-100 |
| >Company | >Ingredient | >NDC |
tazemetostat drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 8000
tazemetostat drug variants containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| Epizyme Inc | tazemetostat | 72607-100 |
| >Company | >Ingredient | >NDC |
tazemetostat drug variants not containing POLYETHYLENE GLYCOL 8000
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM STARCH GLYCOLATE TYPE A POTATO
tazemetostat drug variants containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| Epizyme Inc | tazemetostat | 72607-100 |
| >Company | >Ingredient | >NDC |
tazemetostat drug variants not containing SODIUM STARCH GLYCOLATE TYPE A POTATO
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
tazemetostat drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Epizyme Inc | tazemetostat | 72607-100 |
| >Company | >Ingredient | >NDC |
tazemetostat drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
tazemetostat drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Epizyme Inc | tazemetostat | 72607-100 |
| >Company | >Ingredient | >NDC |
tazemetostat drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch